Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
GABA systemEtizolam
Etizolam is a synthetic depressant of the thienodiazepine class — a structural variant of the benzodiazepine family. It is closely related to alprazolam, binding the same receptor site with higher affinity.[1] It amplifies GABA — the brain's main inhibitory signal — producing anxiety relief, sedation, and muscle relaxation.
Etizolam is a synthetic depressant of the thienodiazepine class. It is structurally related to benzodiazepines like alprazolam, with higher binding affinity at the benzodiazepine site.[1] Etizolam is a positive allosteric modulator at GABA-A receptors, producing its effects by enhancing inhibitory neurotransmission, with an additional platelet-activating factor antagonist mechanism.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
+1 more
GABA systemDeveloped by Yoshitomi Pharmaceutical in Japan in the early 1970s, it reached the market as Depas around 1983–1984 for anxiety and insomnia.[2] From around 2007 it spread through research chemical markets and became one of the most frequently detected designer benzodiazepines worldwide.[3] It was placed in US Schedule I in April 2026, while remaining a prescription medication in Japan, India, and Italy.[4]
Subjective effects include anxiety suppression, sedation, muscle relaxation, and anterograde amnesia. The experience is a rapid dissolution of tension — lighter and cleaner than most benzodiazepines at equivalent anxiolytic doses. Disinhibition, compulsive redosing, and delusions of sobriety are characteristic unwanted effects.[5]
Etizolam produces high physical and psychological dependence;[6] alone, its acute toxicity is relatively low. The dominant danger is combination with opioids — it led all benzodiazepines detected in Ontario opioid-positive death investigations from 2017–2021,[7] and genetic differences in metabolism can increase blood levels up to sixfold.[8] Clinical trials from 1989 to 2009 provide a moderate evidence base,[9] though human pharmacokinetic characterization remains incomplete.
History[edit]
Discovery
Etizolam was developed by Yoshitomi Pharmaceutical Industries in Japan in the early 1970s.[2] The compound replaced the benzene ring of standard benzodiazepines with a thiophene ring — a structural change intended to deliver anxiolytic effects with reduced sedation. It reached the Japanese market around 1983–1984 as Depas and was later approved in Italy and India under brand names including Etilaam and Etizest.[10]
Clinical Research
Randomized controlled trials between 1989 and 2009 confirmed efficacy in panic disorder,[11] generalized anxiety,[9] and anxiety with comorbid depression.[12] A comparative trial found etizolam equivalent in anxiolytic effect to alprazolam, with a notably stronger antidepressant component.[13] At low doses cognitive function was preserved,[14] though supratherapeutic doses produced significant cognitive impairment — the claimed advantage did not hold.[5]
Emergence in Illicit Markets
From around 2007, etizolam appeared in online research chemical markets and illicit drug supplies across Europe and North America.[3] It was found in counterfeit alprazolam tablets and increasingly as an adulterant in the unregulated opioid supply.[15] In Ontario from 2017–2021, it was the most frequently detected benzodiazepine in opioid-positive death investigations.[7]
The name etizolam reflects its structure: eti- references the ethyl group, -zol- the triazole ring, and -am follows benzodiazepine naming convention. In Japan it is best known as Depas; in India, Etilaam and Etizest dominate. Etizolam occupies a distinctive position — simultaneously a legitimate pharmaceutical in some countries and a leading designer benzodiazepine in others, a duality that has complicated both regulation and user risk perception.
Chemistry[edit]
Structural Class
Etizolam belongs to the thienotriazolodiazepine class — a variant of the benzodiazepine scaffold in which the benzene ring is replaced by a thiophene ring, with a triazole ring fused to the diazepine core. Related compounds include clotiazepam and brotizolam.
The substitutions were designed to favor anxiety relief over sedation, and the 2-chlorophenyl group, ethyl group at position 4, and methyl group on the triazole ring are the primary determinants of receptor binding.[16] Its molecular formula is C₁₇H₁₅ClN₄S (molecular weight 342.8 g/mol).
Physical Properties
Moderate lipophilicity supports efficient gut absorption and rapid passage into the brain, consistent with its fast oral onset.[17] In postmortem blood samples, etizolam degrades through a hemoglobin-mediated reaction[18] — so published postmortem concentrations may underestimate what was present during life.
Pharmacology[edit]
Mechanism of Action
Etizolam amplifies GABA — the brain's main inhibitory signal — by binding GABA-A receptors and enhancing their response.[6] It acts as a partial agonist at the most common receptor subtype, reaching a ceiling below full agonists like diazepam[1] — possibly explaining preserved cognition at therapeutic doses.[14] It also blocks platelet-activating factor, an anti-inflammatory effect not shared by most benzodiazepines.[19][20]
Pharmacokinetics
Peak blood levels arrive 0.5–2 hours after oral dosing.[21] The liver metabolizes etizolam primarily via CYP3A4,[22] with CYP2C19 also involved.[8] The major active metabolite, alpha-hydroxyetizolam, is roughly as potent as the parent compound and has a half-life of about 8.2 hours, extending the total duration of effect.[21]
People with CYP2C19 slow metabolism — roughly 3–5% of Europeans and 15–20% of East Asians — have blood levels 2.65 times higher than average.[8] When a CYP3A4 inhibitor such as itraconazole, ketoconazole, or certain HIV medications is also taken, combined exposure can reach 6.18 times normal.[23]
Neuroscience[edit]
Where It Acts
Etizolam's effects arise from enhanced inhibitory signaling across multiple brain regions. Anxiety relief is driven primarily through GABA-A receptors in the amygdala and cortical areas that process fear.[6] Sedation follows from suppressed activity in the brain's arousal systems — EEG studies show etizolam produces greater drowsiness than the related compound clotiazepam.[24]
Why It Matters
Etizolam's partial agonism at the main GABA-A receptor subtype[1] makes it a test case for whether different receptor subtypes drive different effects — anxiety suppression through one, sedation through another. At low doses that separation holds.[14] At high doses cognitive impairment appears regardless[5] — the theoretical advantage collapses with escalating exposure.
Whether etizolam's partial agonism truly produces differential effects across receptor subtypes has not been directly measured.[5] The cognitive deficits seen at high doses may be reversible adaptation or lasting structural change — no neuroimaging data exist to distinguish between them. Its platelet-activating factor antagonism[19] suggests possible neuroprotective applications that remain entirely unexplored.
Subjective Effects[edit]
The etizolam experience is defined by what it removes. Anxiety dissolves within minutes, replaced by a smooth, enveloping calm where emotional and physical distress recede into the background. At lower doses, the mind quiets without becoming heavy — a quality that sets it apart from more sedating benzodiazepines.
Compared to alprazolam at equivalent anxiolytic doses, etizolam is generally reported as lighter and cleaner — less initial sedative weight. At supratherapeutic doses this distinction collapses: amnesia, disinhibition, and motor impairment emerge, indistinguishable from high-dose use of any potent benzodiazepine.
Developed by Yoshitomi Pharmaceutical in 1970s Japan and marketed as Depas, etizolam holds medical approval in Japan, Italy, and India for anxiety and insomnia.[3] From approximately 2007 it became one of the most prevalent novel benzodiazepines in illicit drug markets worldwide.[4] It was permanently placed in US Schedule I in April 2026 while remaining a prescription medication in three countries.[5]
Subjective effects include anxiety suppression, sedation, muscle relaxation, and anterograde amnesia. The experience is one of rapid tension dissolution and cognitive quieting — a smooth, enveloping calm that blunts emotional distress and physical unease without the heavy intoxication characteristic of other depressants at equivalent anxiolytic doses. Disinhibition, compulsive redosing, delusions of sobriety, and pronounced cognitive impairment at high doses[6] are characteristic unsought effects.
Etizolam produces high physical and psychological dependence,[7] though its acute toxicity alone is relatively low. Fatalities escalate sharply in combination with opioids — it was the most frequently detected benzodiazepine in Ontario opioid-positive death investigations from 2017–2021[8] — and genetic variation in CYP2C19 metabolism creates up to 2.65-fold differences in plasma exposure between individuals.[9] Clinical trials from the late 1980s through 2009 provide a moderate evidence base,[10] though human pharmacokinetic characterization remains incomplete.
History[edit]
Discovery
Etizolam was developed by Yoshitomi Pharmaceutical Industries in Japan during the early 1970s.[3] The compound replaced the benzene ring of classical benzodiazepines with a thiophene ring fused to a triazole ring — a structural modification intended to deliver anxiolytic effects with reduced sedation and dependence. It received marketing approval in Japan as Depas around 1983–1984 for generalized anxiety disorder, panic disorder, and insomnia, and was subsequently approved in Italy and India under brand names including Etilaam and Etizest.[11]
Clinical Research
Between 1989 and 2009, randomized controlled trials — predominantly in Italian and Japanese settings — established etizolam's efficacy in panic disorder,[12] generalized anxiety,[10] and anxiety with comorbid depression.[13] A comparative trial found 0.5 mg etizolam equivalent in anxiolytic effect to 0.5 mg alprazolam and 3 mg bromazepam, with a notably stronger antidepressant component.[14] A 2009 multicenter trial showed no significant cognitive impairment at 0.5 mg twice daily, initially supporting claims of a cognitive safety advantage over full-agonist benzodiazepines.[15]
Emergence in Illicit Markets
From approximately 2007, etizolam appeared in online research chemical markets and illicit drug supplies across Europe and North America.[4] It was identified in counterfeit alprazolam tablets, as a standalone product, and increasingly as an adulterant in the unregulated opioid supply.[16] By the mid-2010s it ranked among the three most frequently detected designer benzodiazepines in postmortem and driving-under-the-influence cases worldwide,[16] and in Ontario from 2017–2021 it was the most frequently detected benzodiazepine in opioid-positive death investigations.[8]
The name etizolam derives from its structural components: the eti- prefix references the ethyl group at position 4, -zol- reflects the triazole ring, and -am follows benzodiazepine naming convention. In Japan it is best known by its brand name Depas; in Indian markets, Etilaam and Etizest are the dominant brands. The compound occupies a distinctive position in drug culture — simultaneously a legitimate pharmaceutical in some countries and a leading "designer benzodiazepine" in others — a duality that has complicated both regulatory responses and user risk perception.
Chemistry[edit]
Structural Class
Etizolam belongs to the thienotriazolodiazepine class, a variation on the classical benzodiazepine scaffold in which the benzene ring is replaced by a thiophene ring, with an additional triazole ring fused to the diazepine core. This family includes related anxiolytics such as clotiazepam and brotizolam, though etizolam's specific triazole fusion distinguishes it within the group.
The structural modifications — thiophene for benzene, triazole fusion — were designed to produce anxiolytic selectivity with reduced sedation. The 2-chlorophenyl group at position 7, the ethyl group at position 4, and the methyl group on the triazole ring are the primary determinants of receptor binding and activity.[17]
Molecular Properties
| Molecular formula | C₁₇H₁₅ClN₄S |
| Molecular weight | 342.8 g/mol |
The molecule features a seven-membered diazepine ring fused to a five-membered thiophene ring and a five-membered triazole ring, with a 2-chlorophenyl pendant group. The chlorine atom at the ortho position of the phenyl ring contributes to receptor binding characteristics. The ethyl group at position 4 distinguishes etizolam from brotizolam, which carries a bromine at the equivalent position.
Stereochemistry
Etizolam is used as a racemic mixture. Whether its individual enantiomers differ in binding affinity, metabolism, or clinical effect has not been investigated — a notable gap given demonstrated stereoselective pharmacology in several classical benzodiazepines.
Physical Properties
The compound's moderate lipophilicity (LogP 2.63) supports efficient absorption from the gut and penetration into the central nervous system, consistent with its rapid oral onset.[18] Published data on solubility, salt forms, and storage stability are absent from the peer-reviewed literature.
Etizolam undergoes significant decomposition in postmortem blood samples via a hemoglobin-mediated reaction, generating metabolites that complicate forensic quantification.[19] Published postmortem blood concentrations may therefore systematically underestimate what was present during life.
Pharmacology[edit]
Mechanism of Action
Etizolam is a positive allosteric modulator of GABA-A receptors — the brain's principal fast inhibitory receptors.[7] It binds at the benzodiazepine site on these receptors and enhances the flow of chloride ions when GABA is present, amplifying the brain's own inhibitory signaling. This produces the compound's anxiolytic, sedative, muscle relaxant, anticonvulsant, and amnestic effects.
At the most common GABA-A receptor subtype, etizolam behaves as a partial agonist — it enhances receptor activity but reaches a ceiling below the maximum potentiation produced by full agonists like diazepam.[1] This partial agonist profile has been proposed to explain reduced sedation and cognitive impairment at therapeutic doses,[15] though high-dose dependence with cognitive deficits has been documented, suggesting the advantage may not hold at supratherapeutic exposure.[6]
A secondary mechanism distinguishes etizolam from most benzodiazepines: it acts as a platelet-activating factor (PAF) receptor antagonist.[2][20] This anti-inflammatory property has been used clinically to reduce recurrence of chronic subdural hematoma[2] and investigated for neuroprotective effects in animal brain injury models.[20]
Pharmacokinetics
Etizolam is absorbed rapidly after oral administration, reaching peak blood levels within 0.5–2 hours.[21] Its moderate lipophilicity allows efficient passage into the brain.[18] No published data exist for oral bioavailability, protein binding, or volume of distribution in humans.
The half-life varies significantly depending on genetics. Early studies reported a mean half-life of 3.4 hours,[21] but pharmacogenomic research found longer values: approximately 10.5 hours in normal metabolizers and 14.8 hours in slow metabolizers (CYP2C19 poor metabolizers).[9] At therapeutic doses, the drug does not accumulate meaningfully with twice-daily dosing.[21]
Etizolam is broken down primarily by the liver enzyme CYP3A4,[22] with secondary involvement of CYP2C19.[9] Its major active metabolite, alpha-hydroxyetizolam, is roughly as potent as the parent compound and has a longer half-life of approximately 8.2 hours — contributing significantly to the total duration of effect.[21]
Individuals who are CYP2C19 poor metabolizers (approximately 3–5% of European and 15–20% of East Asian populations) experience 2.65-fold higher blood levels than normal metabolizers.[9] When a CYP3A4 inhibitor is also present, the combined effect can produce a 6.18-fold increase in drug exposure[23] — a pharmacokinetic interaction with serious overdose implications.
Neuroscience[edit]
Where It Acts
Etizolam's effects arise from enhanced inhibitory signaling across multiple brain regions. Anxiety suppression is driven primarily through GABA-A receptors in the amygdala and cortical regions involved in fear processing.[7] Sedation results from suppressed activity in the brain's arousal systems, including the reticular activating system and thalamic relay nuclei — EEG studies confirm that etizolam produces global cortical inhibition with more drowsiness than the related compound clotiazepam.[24]
Muscle relaxation arises from enhanced inhibition of motor neurons in the spinal cord, while the amnestic effects at higher doses reflect disrupted memory formation in the hippocampus, where benzodiazepine-site ligands impair the cellular process underlying new memory encoding.
Why It Matters
Etizolam's partial agonist profile at the most common GABA-A receptor subtype[1] positions it as a test case for the theory that different receptor subtypes drive different effects — anxiolysis through one set, sedation through another. If this model holds, partial agonism at the sedation-linked subtype should provide a wider window between anxiety relief and drowsiness. Clinical data at low doses support this prediction,[15] but severe cognitive impairment at high doses suggests the advantage collapses with escalating exposure.[6]
Key gaps remain in understanding etizolam's neuroscience. Whether its partial agonist profile produces truly differential effects across GABA-A receptor subtypes has not been directly measured — a question critical to understanding its therapeutic window. The cognitive deficits documented at high doses[6] may reflect reversible functional changes or lasting structural neuroadaptation, but no follow-up or neuroimaging data exist to distinguish between these possibilities.
Subjective Effects[edit]
The etizolam experience centers on a rapid dissolution of tension and mental noise. Anxiety lifts within minutes of onset, replaced by a smooth, pervasive calm in which emotional and physical distress recede into the background. At lower doses, this anxiolysis arrives with minimal sedation or cognitive dulling — a quality that distinguishes etizolam from heavier benzodiazepines. As dose increases, the experience shifts toward pronounced sedation, motor impairment, and anterograde amnesia, with a compulsive quality driven by the conviction of being less impaired than one actually is.
Compared to alprazolam at equivalent anxiolytic doses, etizolam is generally reported as lighter and cleaner in its initial anxiolysis, with less immediate sedative weight. At supratherapeutic doses this distinction collapses: the full benzodiazepine spectrum of amnesia, disinhibition, and motor impairment emerges, indistinguishable in character from high-dose use of any potent benzodiazepine-site agonist.
Effect Grid
Clear anxiety suppression and moderate sedation define this range. Muscle relaxation is prominent — noticeable loosening of skeletal muscle tension throughout the body. Cognitive euphoria may emerge as a warm sense of contentment and mental quieting. Thought deceleration is apparent, with reduced speed and volume of internal dialogue.
Mild motor control impairment is possible, particularly at the upper end. Appetite enhancement is commonly reported. Dizziness may occur transiently. This range corresponds to the standard therapeutic dose (0.5 mg twice daily) at which cognitive safety was demonstrated in the De Candia 2009 RCT.
The full subjective experience lasts 5–7 hours. The active metabolite alpha-hydroxyetizolam extends aftereffects for 6–24 hours, during which residual sedation and subtle cognitive impairment may persist. CYP2C19 poor metabolizers experience effects equivalent to a strong dose at this level.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Depth perception distortion · Visual haze / noise · Visual processing suppression
Bodily heaviness · Body high · Breathing alteration · Dizziness · Nystagmus (eye wobbles) · Laughter fits · Nausea · Restlessness · Temperature dysregulation
Dizziness · Nystagmus (eye wobbles) · Laughter fits · Nausea · Restlessness
Focus suppression · Information processing suppression · Creativity suppression · Language suppression · Memory fragmentation · Memory suppression · Motivation suppression · Suggestibility enhancement · Thought deceleration · Cognitive euphoria · Confusion · Thought disorganization · Compulsive redosing urge · Humor enhancement · Amnesia · Delirium
Language suppression · Memory fragmentation · Memory suppression · Motivation suppression · Thought deceleration · Cognitive euphoria · Confusion · Thought disorganization · Compulsive redosing urge · Humor enhancement · Amnesia · Delirium
Dysphoria · Emotional lability · Irritability
Trust enhancement · Automaticity · Sociability suppression · Social disconnection · Communication enhancement · Depersonalization · Derealization · Cognitive disconnection
Communication enhancement · Depersonalization · Derealization · Cognitive disconnection
Timeline
First perceptible effects emerge — a subtle easing of tension and slight cognitive quieting. The shift is gradual and may initially be attributed to placebo.
Progressive anxiolysis and sedation build steadily. Muscle relaxation becomes apparent. Mental chatter slows and emotional tone shifts toward equanimity.
Maximum anxiolysis, sedation, and muscle relaxation. Cognitive euphoria may be present. At higher doses, anterograde amnesia and motor impairment emerge.
Gradual return of baseline anxiety and cognitive speed. Sedation persists and motor impairment may outlast the subjective peak. Physical fatigue becomes noticeable.
Residual sedation, physical fatigue, and emotional blunting driven by the active metabolite alpha-hydroxyetizolam (t½ 8. 2h). Cognitive performance may remain subtly impaired.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · thienodiazepines · Z-drugs
Toxicity
Acute Toxicity
Etizolam presents relatively low acute toxicity on its own — a comprehensive review found it no more harmful than other benzodiazepines at prescribed levels.[6] Deaths from etizolam alone are extremely rare. In a series of 24 etizolam-positive postmortem cases, 87.5% involved multiple drugs — most commonly pregabalin, opioids, or other depressants.[25][26]
Chronic Toxicity
Chronic high-dose use — documented at 15 mg/day — produced deficits in working memory, spatial memory, and executive function.[5] Whether these represent lasting brain changes or reversible adaptation has not been determined.
Involuntary eyelid spasms (blepharospasm) have been linked to etizolam use,[27] with symptoms typically improving within about four weeks of stopping.[28]
Epidemiology
Etizolam-associated fatalities are driven by its presence in unregulated drug supplies:
- Ontario, Canada (2017–2021): Most frequently detected benzodiazepine in 11,033 opioid-positive death investigations[7]
- Alberta, Canada (2020–2022): Among the most commonly detected benzodiazepines in fentanyl co-ingestion fatalities[29]
- International (2019–2020): One of three most frequently detected designer benzodiazepines in postmortem and impaired driving cases[15]
- Australia (2000–2025): Detected in novel benzodiazepine-related poisoning deaths[30]
- Japan: The most commonly abused hypnotic and anxiolytic medication[31]
Psychological Risks
The primary psychological risk at therapeutic doses is anterograde amnesia[18] — the inability to form new memories during the experience. At low doses cognition is preserved.[14] At higher doses amnesia becomes pronounced, and individuals may redose without remembering prior doses, creating a dangerous compulsive cycle.
Delusions of sobriety — the conviction of being unimpaired while objectively intoxicated — is a characteristic risk, particularly dangerous when driving or making dosing decisions. Disinhibition ranges from mild social loosening to impulsive and aggressive behavior at higher doses. Abrupt discontinuation after dependence can produce rebound effect anxiety worse than the original baseline.
Tolerance and Dependence
Tolerance
Tolerance to sedative and anxiolytic effects develops within days of continuous use. Cross-tolerance with other benzodiazepines is expected due to shared receptor pharmacology. Whether etizolam's partial agonist profile slows tolerance development compared to full agonists remains unconfirmed in human studies.
Dependence
Physical and psychological dependence potential is high — comparable to classical benzodiazepines.[6] Documented cases include patients who escalated from therapeutic to supratherapeutic doses after initial medical prescription.[5] The trajectory from legitimate prescription to dependence is well-established.
Withdrawal
No etizolam-specific withdrawal protocols have been published. Management follows standard benzodiazepine principles: gradual dose tapering, possible substitution with a longer-acting benzodiazepine, and seizure precautions.inferred The risk of seizures on abrupt discontinuation after physical dependence must be assumed. The short half-life of the parent compound may produce earlier withdrawal onset than long-acting benzodiazepines.
Drug Interactions
Opioid Synergy
The combination of etizolam with opioids — particularly fentanyl — produces synergistic respiratory depression and is the primary driver of etizolam-associated mortality. This combination is never safe at any dose.
Etizolam was the most frequently detected benzodiazepine in opioid-positive death investigations in Ontario (2017–2021).[7] In Alberta fentanyl fatalities, benzodiazepine-positive cases had higher fentanyl blood levels than benzodiazepine-negative cases, suggesting co-ingestion may mask respiratory warning signs.[29]
Metabolic Interactions
Drugs that inhibit CYP3A4 — including itraconazole, ketoconazole, clarithromycin, and some HIV medications — significantly increase etizolam blood levels.[23] In CYP2C19 slow metabolizers also taking such a drug, blood levels can reach 6.18 times normal — a combination that creates serious overdose risk.[23]
Other Depressants
All CNS depressants produce additive effects when combined with etizolam: alcohol, other benzodiazepines, barbiturates, sedating antihistamines, antipsychotics, and tricyclic antidepressants.
SSRIs
Two case reports describe serotonin syndrome — potentially life-threatening overheating and muscle rigidity — in patients taking SSRIs concurrently with etizolam.[32] Etizolam has no known serotonergic activity; these cases likely reflect SSRI-driven serotonin syndrome, with etizolam's sedation potentially masking early warning signs.
Contraindications
10 knownAbsolute
- Concurrent opioid use: Synergistic respiratory depression with high fatality risk[7][29]
- Concurrent alcohol use: Additive central nervous system depression
- Myasthenia gravis: GABA-A enhancement worsens neuromuscular weaknessinferred
- Acute angle-closure glaucoma: Benzodiazepine class contraindicationinferred
Relative
- CYP2C19 poor metabolizers taking CYP3A4 inhibitors: 6.18-fold increase in drug exposure creates overdose risk[23]
- Sleep apnea: Worsens airway obstruction and breathing drive suppressioninferred
- Pregnancy: Risk of neonatal withdrawal; no etizolam-specific datainferred
- Breathing difficulties: Any pre-existing respiratory compromise increases riskinferred
- Elderly patients: Increased sensitivity, fall risk, and slower metabolism
- History of substance use disorder: High reinforcement potential due to rapid onset and high binding affinity[5]
Harm Reduction[edit]
Forms & Identification
Etizolam exists as a pharmaceutical in some countries and an unregulated substance in others. Pharmaceutical tablets from Japan or India carry standardized doses; pressed pills, blotters, and powders from unregulated sources do not. Standard hospital and workplace drug screens typically miss etizolam entirely.[33]
Powder and liquid forms demand particular caution. Active doses are measured in fractions of a milligram — small measurement errors produce large changes in effect. A milligram-precision scale is essential for powder; volumetric dosing is the most reliable approach for precise sub-milligram measurement.
Guidelines
- Test all substances from unregulated sources before use
- Pre-measure a single dose and store the remaining supply separately — etizolam-induced amnesia can lead to unintentional redosing
- Start with the lowest effective dose, especially with a new or untested source
- Do not drive or operate machinery — impairment may be present despite feeling sober
- Avoid daily use; tolerance develops within days of continuous administration and dependence follows rapidly
- Inform a trusted person of the substance taken and the timing
- Use volumetric dosing for powder or liquid forms — milligram-scale measurement errors are clinically significant at this potency
Set & Setting
Etizolam's anxiolytic effects can create a false sense of normalcy — the sensation of being completely fine while cognitive and motor function are measurably impaired. This makes impairment less obvious to the person experiencing it than with most intoxicants.
Pre-measuring a single intended dose and securing the remainder out of reach substantially reduces the risk of compulsive redosing. Amnesia and delusions of sobriety make it easy to lose track of what has been taken.
Aftercare & integration. Allow adequate recovery time before resuming activities requiring full cognitive and motor function. Residual sedation and impairment from the active metabolite may persist 6–24 hours after the subjective peak fades.
If memory gaps occurred during use, reconstruct events with a trusted person. Amnesia may indicate the dose exceeded a safe threshold for future reference. If use has become regular, do not stop abruptly — seek medical guidance on tapering.
Recovery & Support
Etizolam dependence carries the same risks as benzodiazepine dependence: abrupt cessation after regular use can produce life-threatening seizures. Medical supervision for withdrawal is strongly recommended. A gradual tapering protocol — often substituting a longer-acting benzodiazepine under medical guidance — is the standard approach.
Recovery resources include benzodiazepine-specific communities (Benzodiazepine Information Coalition, BenzoBuddies), general substance use support (SMART Recovery, mutual aid groups), and clinical addiction services. Cognitive recovery from chronic high-dose use may take weeks to months.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Extreme sedation or inability to be roused
- Slow, shallow, or stopped breathing
- Blue or grey discoloration of lips or fingertips
- Seizures
- Loss of consciousness
Immediate steps:
- Call emergency services immediately if breathing is slow, stopped, or the person cannot be woken
- Place the person in the recovery position (on their side) to prevent choking
- Do not leave them alone
- Do not induce vomiting
- If opioid co-ingestion is suspected or possible, administer naloxone — it will not reverse etizolam's effects but may counter opioid-related respiratory depression
- Monitor breathing continuously until help arrives
What to tell the dispatcher: Name the substance (etizolam or "a benzodiazepine-type drug"), the approximate amount and time of ingestion, any other substances involved, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agents: No specific reversal agent for etizolam is available outside hospital settings. Flumazenil (a benzodiazepine antagonist) exists but carries seizure risk in dependent individuals and is administered only by medical professionals.
Legal Status[edit]
Etizolam is a prescription medication in Japan, India, and Italy, and a controlled substance in most other jurisdictions — a split driven by divergent views on its therapeutic value versus the harms documented in illicit markets.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Permanent since April 1, 2026; no approved medical use under federal law[4] |
| United Kingdom | Class C, Schedule 1 (Misuse of Drugs Act 1971) | Classified May 2017; previously captured under Psychoactive Substances Act 2016[34] |
| Japan | Prescription medication | Approved as Depas for anxiety, panic disorder, insomnia; scheduling tightened due to abuse patterns[31] |
| India | Prescription only | Marketed as Etilaam, Etizest[10] |
| Italy | Prescription only | Approved for medical use[10] |
| Australia | Schedule 4 (SUSMP) | Import requires Office of Drug Control license[35] |
| Canada | Schedule VI (CDSA) | Controlled as benzodiazepine derivative; not individually licensed for medical use[36] |
| International (UN) | Schedule IV (Convention on Psychotropic Substances) | Placed March 2020; signatory states required to implement domestic controls[37] |
Legal status changes frequently and varies significantly by jurisdiction. This information is not legal advice. Verify current status before making any decisions.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Moderate
- Withdrawal
- Severe
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- High
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- benzodiazepines · thienodiazepines · Z-drugs
Toxicity
Acute Toxicity
At therapeutic doses, etizolam presents relatively low acute toxicity — a comprehensive review concluded it is no more harmful than other benzodiazepines at prescribed levels.[7] Animal data indicate lower acute lethality than diazepam.[7] No human lethal dose has been established.
Deaths from etizolam alone are extremely rare. In a series of 24 etizolam-positive postmortem cases, multi-drug toxicity caused 87.5% of deaths, with pregabalin, morphine/heroin, diazepam, and cocaine detected in the majority.[25] The typical fatal scenario involves etizolam combined with other depressants — one case documented etizolam (86 ng/mL) combined with phenobarbital (5082 µg/mL), promethazine, and chlorpromazine.[26]
Chronic Toxicity
Chronic high-dose use (15 mg/day) produced measurable cognitive impairment: deficits in working memory, spatial memory, and executive function.[6] Whether these represent lasting brain changes or reversible adaptation has not been determined.
Drug-induced blepharospasm (involuntary eyelid spasms) has been linked to etizolam,[27] with symptoms improving within approximately four weeks of cessation.[28]
Epidemiology
Etizolam-associated fatalities are driven by its presence in unregulated drug supplies:
- Ontario, Canada (2017–2021): Most frequently detected benzodiazepine in 11,033 opioid-positive death investigations[8]
- Alberta, Canada (2020–2022): Among the most commonly detected benzodiazepines in fentanyl co-ingestion fatalities[29]
- International (2019–2020): One of three most frequently detected designer benzodiazepines in postmortem and impaired driving cases[16]
- Australia (2000–2025): Detected in novel benzodiazepine-related poisoning deaths[30]
- Japan: The most commonly abused hypnotic and anxiolytic medication[31]
Psychological Risks
The primary psychological risk at therapeutic doses is anterograde amnesia.[19] At low doses (0.5 mg twice daily), cognitive function is preserved.[15] At higher doses, amnesia becomes pronounced — individuals may redose without remembering prior doses, producing a dangerous compulsive redosing cycle.
Delusions of sobriety — the subjective conviction of being unimpaired while objectively intoxicated — is a characteristic risk. This is particularly dangerous when driving, operating machinery, or making dosing decisions.
Disinhibition ranges from mild social loosening to impulsive and aggressive behavior at higher doses. Abrupt discontinuation after dependence can produce rebound effect anxiety exceeding baseline severity.
Tolerance and Dependence
Tolerance
Tolerance to sedative and anxiolytic effects develops with repeated use, with onset estimated within days of continuous administration. Cross-tolerance with benzodiazepines and other thienodiazepines is expected based on shared receptor pharmacology. Whether etizolam's partial agonist profile slows tolerance development compared to full agonists has been proposed but not confirmed in human studies.
Dependence
Physical and psychological dependence potential is high, comparable to classical benzodiazepines.[7] A study documented 11 patients who escalated from therapeutic to supratherapeutic doses after initial medical prescription, identified among 1,293 admissions to a detoxification unit.[6] The trajectory from legitimate prescription to dependence is well-documented.
Withdrawal
No etizolam-specific withdrawal protocols have been published. Management follows standard benzodiazepine withdrawal principles: gradual dose tapering, possible substitution with a longer-acting benzodiazepine, and seizure precautions.inferred The risk of seizures on abrupt discontinuation after physical dependence must be assumed. The relatively short half-life of the parent compound may produce earlier withdrawal onset than long-acting benzodiazepines.
Drug Interactions
Opioid Synergy
The combination of etizolam with opioids — particularly fentanyl and its analogues — produces synergistic respiratory depression and is the primary driver of etizolam-associated mortality. This combination is never safe at any dose.
Etizolam was the most frequently detected benzodiazepine in opioid-positive death investigations in Ontario (2017–2021).[8] In Alberta fentanyl fatalities, benzodiazepine-positive cases had higher fentanyl blood levels than benzodiazepine-negative cases, suggesting that benzodiazepine co-ingestion may mask respiratory depression warning signs.[29]
Metabolic Interactions
Drugs that inhibit CYP3A4 (including itraconazole, ketoconazole, clarithromycin, and HIV protease inhibitors) significantly increase etizolam blood levels — by 1.66-fold in normal metabolizers and 2.34-fold in slow metabolizers.[23] The worst-case scenario — a CYP2C19 poor metabolizer taking a potent CYP3A4 inhibitor — produces a 6.18-fold increase in etizolam exposure.[23]
Other Depressants
All CNS depressants produce additive effects when combined with etizolam: alcohol, other benzodiazepines, barbiturates, sedating antihistamines, antipsychotics, and tricyclic antidepressants.
SSRIs
Two case reports describe serotonin syndrome in patients taking SSRIs concurrently with etizolam.[32] Etizolam has no known serotonergic activity — these cases likely reflect SSRI-driven serotonin syndrome, with the concern that etizolam's sedation may mask early warning signs.
Contraindications
10 knownAbsolute
- Concurrent opioid use: Synergistic respiratory depression with high fatality risk[8][29]
- Concurrent alcohol use: Additive depression of the central nervous system
- Myasthenia gravis: GABA-A enhancement worsens neuromuscular weaknessinferred
- Acute angle-closure glaucoma: Benzodiazepine class contraindicationinferred
Relative
- CYP2C19 poor metabolizers taking CYP3A4 inhibitors: 6.18-fold increase in drug exposure creates overdose risk[23]
- Sleep apnea: Worsens airway obstruction and breathing drive suppressioninferred
- Pregnancy: Risk of neonatal withdrawal; no etizolam-specific datainferred
- Breathing difficulties: Any pre-existing respiratory compromise increases riskinferred
- Elderly patients: Increased sensitivity, fall risk, and slower metabolism
- History of substance use disorder: High reinforcement potential due to rapid onset and high binding affinity[6]
Harm Reduction[edit]
Forms & Identification
Etizolam's dual existence as a pharmaceutical product and an unregulated substance means the same compound can arrive in radically different forms with radically different reliability. Pharmaceutical tablets from Japan or India carry standardized doses; pressed pills, blotters, and powders from unregulated sources do not. Standard workplace and hospital drug screens typically miss etizolam entirely,[33] making reagent testing especially important for harm reduction purposes.
Powder and liquid forms demand particular caution. Active doses are measured in fractions of a milligram, and small measurement errors translate to large changes in effect. A milligram-precision scale is essential for powder; volumetric dosing (dissolving a weighed amount in a measured volume of liquid) is the most reliable approach for precise dosing.
Guidelines
- Test all substances from unregulated sources before use
- Pre-measure a single dose and store remaining supply separately — etizolam-induced amnesia can lead to unintentional redosing
- Start with the lowest effective dose, particularly with a new or untested source
- Do not drive or operate machinery — impairment may be present despite feeling sober
- Avoid daily use; tolerance develops within days of continuous administration and dependence follows rapidly
- Inform a trusted person of what you have taken and when
- Use volumetric dosing for powder or liquid forms — milligram-scale measurement errors are clinically significant at this potency
Set & Setting
Etizolam's anxiolytic effects can create a false sense of normalcy — the sensation of being completely fine while cognitive and motor function are measurably impaired. This makes set and setting considerations different from substances where impairment is obvious to the user.
Use in a safe, familiar environment where driving and operating machinery are not needed. The risk of compulsive redosing is heightened by amnesia and delusions of sobriety — pre-measuring a single intended dose and securing the remainder out of immediate reach reduces this risk substantially.
Aftercare & integration. After etizolam use, allow adequate recovery time before resuming activities that require full cognitive and motor function. Residual sedation and impairment from the active metabolite may persist for 6–24 hours after the subjective peak fades.
If memory gaps occurred during use, reconstruct events with a trusted person present. Amnesia during etizolam use is dose-dependent and may indicate the dose exceeded a safe threshold for future reference. If use has become regular, do not stop abruptly — seek medical guidance on tapering.
Recovery & Support
Etizolam dependence carries the same risks as benzodiazepine dependence: abrupt cessation after regular use can produce life-threatening seizures. Medical supervision for withdrawal is strongly recommended. A gradual tapering protocol — often involving substitution with a longer-acting benzodiazepine under medical guidance — is the standard approach.
Recovery resources include benzodiazepine-specific support communities (the Benzodiazepine Information Coalition, BenzoBuddies), general substance use support (SMART Recovery, mutual aid groups), and clinical addiction services. Cognitive recovery from chronic high-dose use may take weeks to months.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
- Extreme sedation or inability to be roused
- Slow, shallow, or stopped breathing
- Blue or grey discoloration of lips or fingertips
- Seizures
- Loss of consciousness
Immediate steps:
- Call emergency services immediately if breathing is slow, stopped, or the person cannot be woken
- Place the person in the recovery position (on their side) to prevent choking
- Do not leave them alone
- Do not induce vomiting
- If opioid co-ingestion is suspected or possible, administer naloxone — it will not reverse etizolam's effects but may counter opioid-related respiratory depression
- Monitor breathing continuously until help arrives
What to tell the dispatcher: Name the substance (etizolam or "a benzodiazepine-type drug"), the approximate amount and time of ingestion, any other substances involved, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Reversal agents: No specific reversal agent for etizolam is available outside hospital settings. Flumazenil (a benzodiazepine antagonist) exists but carries seizure risk in dependent individuals and is administered only by medical professionals.
Legal Status[edit]
Etizolam occupies an unusual regulatory position: it remains an approved prescription medication in Japan, India, and Italy while being classified as a controlled substance in an increasing number of jurisdictions responding to its presence in illicit drug markets. It was placed in Schedule IV of the UN Convention on Psychotropic Substances in March 2020.[34] In the United States, etizolam was permanently placed in Schedule I of the Controlled Substances Act effective April 1, 2026 — the most restrictive classification, prohibiting all medical use and research without DEA authorization.[5]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Permanent since April 1, 2026; no approved medical use under federal law[5] |
| United Kingdom | Class C, Schedule 1 (Misuse of Drugs Act 1971) | Classified May 2017; previously captured under Psychoactive Substances Act 2016[35] |
| Japan | Prescription medication | Approved as Depas for anxiety, panic disorder, insomnia; scheduling tightened due to abuse patterns[31] |
| India | Prescription only | Marketed as Etilaam, Etizest[11] |
| Italy | Prescription only | Approved for medical use[11] |
| Australia | Schedule 4 (SUSMP) | Import requires Office of Drug Control license[36] |
| Canada | Schedule VI (CDSA) | Controlled as benzodiazepine derivative; not individually licensed for medical use[37] |
| International (UN) | Schedule IV (Convention on Psychotropic Substances) | Placed March 2020; signatory states required to implement domestic controls[34] |
The contrast between Schedule I in the United States (no accepted medical use) and continued prescription availability in Japan, India, and Italy reflects divergent regulatory approaches: the US classification responds to illicit market harms, while prescribing jurisdictions maintain that therapeutic utility justifies continued availability under medical supervision.
Frequently asked questions
What is Etizolam?
Etizolam is a thienotriazolodiazepine anxiolytic and sedative-hypnotic, approved in Japan, Italy, and India since the 1980s. It acts as a GABA-A positive allosteric modulator with partial agonist activity at α1-containing receptor subtypes.
How long does Etizolam last?
Total duration by route of administration — Oral: 5 – 7 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Etizolam?
Psychedex publishes a dosage table for Etizolam on this page covering these routes of administration: oral. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Etizolam?
The highest-severity documented interactions for Etizolam: Opioids (Lethal), Alpha-2 adrenergic receptor antagonist (Dangerous), Antipsychotics (Dangerous), Atypical antipsychotics (Dangerous), Benzodiazepines (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Etizolam addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Etizolam: tolerance builds rapid; full reset takes 10.5 days; cross-tolerance develops with benzodiazepines, thienodiazepines, Z-drugs. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abcSanna E, Pau D, Tuveri F, et al. (1999) Molecular and neurochemical evaluation of the effects of etizolam on GABAA receptors under normal and stress conditions. — Arzneimittel-Forschung PMID:10083975
- [2]
- [3] ^abOrsolini L, Corkery JM, Chiappini S, Guirguis A, Vento A, et al. (2020) 'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports — Current Neuropharmacology doi:10.2174/1570159x18666200110121333
- [4]
- [5]
- [6]
references
- [1] ^abcSanna E, Pau D, Tuveri F, et al. (1999) Molecular and neurochemical evaluation of the effects of etizolam on GABAA receptors under normal and stress conditions. — Arzneimittel-Forschung PMID:10083975
- [2] ^abcdHirashima Y, Kuwayama N, Hamada H, Hayashi N, Endo S (2002) Etizolam, an anti-anxiety agent, attenuates recurrence of chronic subdural hematoma--evaluation by computed tomography — Neurologia Medico-Chirurgica PMID:11944589
- [3]
- [4] ^abOrsolini L, Corkery JM, Chiappini S, Guirguis A, Vento A, et al. (2020) 'New/Designer Benzodiazepines': An Analysis of the Literature and Psychonauts' Trip Reports — Current Neuropharmacology doi:10.2174/1570159x18666200110121333
- [5]
- [6]